<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patient survival after BMT is directly correlated with the HLA-type of the donor </plain></SENT>
<SENT sid="1" pm="."><plain>The survival rate after BMT from an HLA-genotypically identical sibling is 56% in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, 55% in combined severe <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> disease (<z:mp ids='MP_0002536'>SCID</z:mp>) and 67/83% in severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>The usage of only HLA-D identical related or unrelated donors in <z:mp ids='MP_0002536'>SCID</z:mp> revealed a 37% survival, compared to 18% survival in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and 11% in severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> using HLA-phenotypical identical or HLA-D identical related donors </plain></SENT>
<SENT sid="3" pm="."><plain>BMT from HLA-phenotypical and MLC identical unrelated donors resulted in <z:hpo ids='HP_0011420'>death</z:hpo> of the grafted patients </plain></SENT>
<SENT sid="4" pm="."><plain>Non of the patients grafted with HLA-different marrow survived BMT </plain></SENT>
<SENT sid="5" pm="."><plain>Survival of BMT patients depended beside the histocompatibility matching on the clinical treatment and the clinical constellation of the patient: The survival rate decreased in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients due to sensibilisation caused by pre-BMT blood transfusion and was significantly higher in <z:hpo ids='HP_0001909'>leukemia</z:hpo> when BMT was performed in remission </plain></SENT>
</text></document>